MA49248A - Inhibiteurs de fgfr2 utilisés dans le traitement du cholangiocarcinome - Google Patents

Inhibiteurs de fgfr2 utilisés dans le traitement du cholangiocarcinome

Info

Publication number
MA49248A
MA49248A MA049248A MA49248A MA49248A MA 49248 A MA49248 A MA 49248A MA 049248 A MA049248 A MA 049248A MA 49248 A MA49248 A MA 49248A MA 49248 A MA49248 A MA 49248A
Authority
MA
Morocco
Prior art keywords
cholangiocarcinoma
treatment
inhibitors used
fgfr2 inhibitors
fgfr2
Prior art date
Application number
MA049248A
Other languages
English (en)
Inventor
Jacqueline Cirillo Bussolari
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MA49248A publication Critical patent/MA49248A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7023—(Hyper)proliferation
    • G01N2800/7028—Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
MA049248A 2017-06-02 2018-06-01 Inhibiteurs de fgfr2 utilisés dans le traitement du cholangiocarcinome MA49248A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17174295 2017-06-02
EP18171315 2018-05-08

Publications (1)

Publication Number Publication Date
MA49248A true MA49248A (fr) 2020-04-15

Family

ID=62555054

Family Applications (1)

Application Number Title Priority Date Filing Date
MA049248A MA49248A (fr) 2017-06-02 2018-06-01 Inhibiteurs de fgfr2 utilisés dans le traitement du cholangiocarcinome

Country Status (16)

Country Link
US (2) US11707463B2 (fr)
EP (1) EP3634414A1 (fr)
JP (2) JP2020521794A (fr)
KR (1) KR20200010505A (fr)
CN (1) CN111050769A (fr)
AU (1) AU2018278271B2 (fr)
BR (1) BR112019025056A2 (fr)
CA (1) CA3064317A1 (fr)
IL (1) IL271058A (fr)
JO (1) JOP20190280A1 (fr)
MA (1) MA49248A (fr)
MX (1) MX2019014366A (fr)
MY (1) MY204203A (fr)
PH (1) PH12019502710A1 (fr)
UA (1) UA126478C2 (fr)
WO (1) WO2018220206A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE053654T2 (hu) 2014-03-26 2021-07-28 Astex Therapeutics Ltd FGFR- és CMET-inhibitorok kombinációi a rák kezelésére
JOP20200201A1 (ar) 2015-02-10 2017-06-16 Astex Therapeutics Ltd تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين
JOP20190280A1 (ar) * 2017-06-02 2019-12-02 Janssen Pharmaceutica Nv مثبطات fgfr2 لعلاج سرطان الأوعية الصفراوية
WO2020165181A1 (fr) * 2019-02-12 2020-08-20 Janssen Pharmaceutica Nv Traitement contre le cancer
WO2020205493A1 (fr) * 2019-03-29 2020-10-08 Janssen Pharmaceutica Nv Inhibiteurs de tyrosine kinase fgfr pour le traitement du carcinome urothélial
KR20220092455A (ko) * 2019-05-28 2022-07-01 큐이디 테라퓨틱스, 인크. 담관암종의 치료 방법
TW202114665A (zh) * 2019-08-05 2021-04-16 大陸商江蘇恆瑞醫藥股份有限公司 一種吡咯并六員雜環化合物在製備治療ｆｇｆｒ２基因變異的腫瘤的藥物中的用途
JP2023512482A (ja) * 2020-01-17 2023-03-27 ベータ・ファーマ・インコーポレイテッド Ｆｇｆｒキナーゼ阻害剤としてのピリダジンおよび１，２，４－トリアジン誘導体
CN111596058A (zh) * 2020-05-18 2020-08-28 山东第一医科大学(山东省医学科学院) 一种检测胆管癌患者外周血循环肿瘤细胞fgfr基因突变的试剂盒及检测方法
DE102021126650A1 (de) 2021-10-14 2023-04-20 Rheinische Friedrich-Wilhelms-Universität Bonn, Körperschaft des öffentlichen Rechts Verfahren zur bestimmung der ansprechwahrscheinlichkeit einer malignen erkrankung auf eine behandlung mit einem pharmazeutischen hemmwirkstoff
KR20250117064A (ko) 2024-01-26 2025-08-04 충북대학교 산학협력단 아무렌신 g를 유효성분으로 포함하는 담관암 예방 또는 치료용 약학적 조성물

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US6218529B1 (en) 1995-07-31 2001-04-17 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer
CA2744096C (fr) 1996-07-31 2013-07-30 Laboratory Corporation Of America Holdings Biomarqueurs et cibles de diagnostic, de pronostic et de traitement du cancer de la prostate
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
NZ563692A (en) 2005-05-23 2011-04-29 Novartis Ag Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one lactic acid salts
US8163923B2 (en) 2007-03-14 2012-04-24 Advenchen Laboratories, Llc Spiro substituted compounds as angiogenesis inhibitors
JP2010525301A (ja) * 2007-03-23 2010-07-22 ザ・トランスレーショナル・ジェノミクス・リサーチ・インスティチュート 子宮内膜癌および前癌の診断、分類および治療の方法
GB201007286D0 (en) * 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
AR088941A1 (es) 2011-11-23 2014-07-16 Bayer Ip Gmbh Anticuerpos anti-fgfr2 y sus usos
US9254288B2 (en) * 2012-05-07 2016-02-09 The Translational Genomics Research Institute Susceptibility of tumors to tyrosine kinase inhibitors and treatment thereof
US10980804B2 (en) * 2013-01-18 2021-04-20 Foundation Medicine, Inc. Methods of treating cholangiocarcinoma
UA122564C2 (uk) 2014-09-26 2020-12-10 Янссен Фармацевтика Нв Використання панелі мутантних генів fgfr для ідентифікації пацієнтів із раковим захворюванням, які піддаються лікуванню інгібітором fgfr
EP3365335B1 (fr) 2015-10-23 2024-02-14 Array Biopharma, Inc. Composés de 2-pyridazin-3(2h)-one à substitution 2-aryle et 2-hétéroaryle utilisés en tant qu'inhibiteurs de fgfr tyrosine kinases
JOP20190280A1 (ar) * 2017-06-02 2019-12-02 Janssen Pharmaceutica Nv مثبطات fgfr2 لعلاج سرطان الأوعية الصفراوية

Also Published As

Publication number Publication date
MY204203A (en) 2024-08-15
US11707463B2 (en) 2023-07-25
UA126478C2 (uk) 2022-10-12
PH12019502710A1 (en) 2020-06-08
US20200138809A1 (en) 2020-05-07
WO2018220206A1 (fr) 2018-12-06
JP2020521794A (ja) 2020-07-27
AU2018278271A1 (en) 2019-12-05
AU2018278271B2 (en) 2024-07-04
JP2023113650A (ja) 2023-08-16
MX2019014366A (es) 2020-07-27
US20240016801A1 (en) 2024-01-18
IL271058A (en) 2020-01-30
JOP20190280A1 (ar) 2019-12-02
US12350266B2 (en) 2025-07-08
CN111050769A (zh) 2020-04-21
KR20200010505A (ko) 2020-01-30
BR112019025056A2 (pt) 2020-06-16
EP3634414A1 (fr) 2020-04-15
CA3064317A1 (fr) 2018-12-06

Similar Documents

Publication Publication Date Title
MA49248A (fr) Inhibiteurs de fgfr2 utilisés dans le traitement du cholangiocarcinome
EP3960735C0 (fr) Dérivés de quinazoline utilisés pour traiter le vih
EP3160475C0 (fr) Nucléosides et nucléotides substitués pour traiter les infections dues aux filoviridae
EP3426250A4 (fr) Procédés de traitement
EP3359171C0 (fr) Utilisation d'akkermansia muciniphila pour traiter des états inflammatoires
EP3370703A4 (fr) Combinaison de gemcabène pour le traitement de maladies cardiovasculaires
HRP20181661T1 (hr) Inhibitori jak1 za liječenje mijelodisplastičnih sindroma
SI3240554T1 (sl) Blautia stercosis in wexlerae za uporabo v zdravljenju vnetnih in avtoimunskih bolezni
EP3601536A4 (fr) Procédés de traitement
EP3263132C0 (fr) Composition pour le traitement de maladies associées à il-6
EP3302379A4 (fr) Compositions et méthodes pour le traitement du ptérygion
EP3504187A4 (fr) Utilisation de la pridopidine pour le traitement du déclin fonctionnel
EP3448263A4 (fr) Traitement électrothérapeutique
EP3519833A4 (fr) Méthodes de pronostic et de traitement
PL3503890T3 (pl) Stosowanie pridopidyny w leczeniu dystonii
EP3341391A4 (fr) Compositions et procédés pour le traitement de la douleur
EP3409744A4 (fr) Agent de traitement de surface
PL3773715T3 (pl) Mirikizumab w leczeniu wrzodziejącego zapalenia jelita grubego
EP3362065A4 (fr) Polythérapie pour le traitement de malignités
EP3431566A4 (fr) Agent de traitement de surface
EP3503904C0 (fr) Traitement par ascaroside de l'oesophagite à éosinophiles
EP3705545A4 (fr) Composition de traitement de surface
DK3710000T3 (da) Tradipitant til anvendelse til behandling af gastroparese
IL245872A0 (en) Process and facility for the treatment of livestock waste
EP3548045C0 (fr) Compositions pour utilisation dans le traitement de l'infection urogénitale